ELIGARD

This brand name is authorized in Australia, Austria, Brazil, Canada, Croatia, Cyprus, Ecuador, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Lithuania, Mexico, Netherlands, Poland, Romania, Singapore, South Africa, Spain, Turkey.

Active ingredients

The drug ELIGARD contains one active pharmaceutical ingredient (API):

1	Leuprorelin UNII 37JNS02E7V - LEUPROLIDE ACETATE
	Leuprorelin is inactive when given orally due to poor membrane permeability and an almost complete inactivation by intestinal proteolytic enzymes. Leuprorelin has potent LHRH agonist properties when given during short-term and intermittent therapy, however, when administered in a continuous, nonpulsatile manner, LHRH analogs induce inhibition of gonadotropin secretion and suppression of testicular steroidogenesis.
	Read more about Leuprorelin

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L02AE02	Leuprorelin	L Antineoplastic and immunomodulating agents → L02 Endocrine therapy → L02A Hormones and related agents → L02AE Gonadotropin releasing hormone analogues
Discover more medicines within L02AE02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	8707G, 8708H, 8709J, 8859G
BR	Câmara de Regulação do Mercado de Medicamentos	534213080009803, 534214090010603, 534214090010703
CA	Health Products and Food Branch	02248239, 02248240, 02248999, 02268892
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	30060-12-11
EE	Ravimiamet	1156755, 1156766, 1156801, 1156812, 1287570, 1287581
ES	Centro de información online de medicamentos de la AEMPS	66620, 66627, 69357
FI	Lääkealan turvallisuus- ja kehittämiskeskus	020427, 059569, 513528
FR	Base de données publique des médicaments	60639255, 62403976, 69267482
HK	Department of Health Drug Office	61498, 61499, 61500
HR	Agencija za lijekove i medicinske proizvode	HR-H-020927799, HR-H-509836130
IE	Health Products Regulatory Authority	88531, 88534, 88598
IL	מִשְׂרַד הַבְּרִיאוּת	7881, 7882, 7883
LT	Valstybinė vaistų kontrolės tarnyba	1004419, 1004420, 1016980, 1016981, 1024891, 1025282
MX	Comisión Federal para la Protección contra Riesgos Sanitarios	626M2003
NL	Z-Index G-Standaard, PRK	78344, 78352, 85111
PL	Rejestru Produktów Leczniczych	100136392, 100136400, 100189773
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W67702006, W67702007, W67816003, W67816004
SG	Health Sciences Authority	14511P, 14512P, 14513P
TR	İlaç ve Tıbbi Cihaz Kurumu	8683161947067, 8699559770148, 8699559770155
ZA	Health Products Regulatory Authority	A39/26/0650, A39/26/0651